title: Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study.
abstract: The efficacy of trazodone (mean once-daily dose 111.5 +/- 36.3 mg) versus clorazepate (mean once-daily dose 17.5 +/- 7.5 mg) to relieve anxious and depressive symptoms in 18 patients undergoing treatment for breast cancer was investigated in a 28-day randomized, double-blind study. Efficacy was evaluated using the Hospital Anxiety and Depression Scale, the Revised Symptom Checklist and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. A successful response to treatment was achieved in 91% (10/11) of patients who received trazodone and 57% (four of seven) of patients who were administered clorazepate (P = 0.1373). Bayesian analysis revealed that the prior probability of making a wrong decision in prescribing trazodone rather than clorazepate reduced from 26% to 8%. Assessment of the clinical scales suggested a benefit of trazodone compared with clorazepate, although the differences were not significant. Safety of both treatments was similar. Trazodone is devoid of an abuse risk and dependence and, therefore, could be a valuable alternative to clorazepate in the treatment of adjustment disorders in cancer patients.
authors.affiliation: Saint Pierre University Hospital, Brussels, Belgium.
authors.forename: D
authors.initials: D
authors.lastname: Razavi
authors.forename: N
authors.initials: N
authors.lastname: Kormoss
authors.forename: A
authors.initials: A
authors.lastname: Collard
authors.forename: C
authors.initials: C
authors.lastname: Farvacques
authors.forename: N
authors.initials: N
authors.lastname: Delvaux
mesh_terms: D000275:Adjustment Disorders / Q000188:drug therapy* / Q000209:etiology; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety; D001943:Breast Neoplasms / Q000523:psychology* / Q000628:therapy; D003009:Clorazepate Dipotassium / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D012449:Safety; D014196:Trazodone / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014151:Anti-Anxiety Agents; D003009:Clorazepate Dipotassium; D014196:Trazodone